Royal Bank of Canada Cuts Perspective Therapeutics (NYSE:CATX) Price Target to $16.00

Perspective Therapeutics (NYSE:CATX) had its price target cut by analysts at Royal Bank of Canada from $25.00 to $16.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Royal Bank of Canada’s price target would suggest a potential upside of 266.13% from the company’s previous close.

A number of other analysts also recently commented on CATX. Bank of America downgraded shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $24.00 to $5.00 in a report on Monday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Truist Financial started coverage on shares of Perspective Therapeutics in a report on Wednesday, September 25th. They set a “buy” rating and a $21.00 price target on the stock. Oppenheimer cut their price target on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, November 22nd. Finally, Wedbush restated an “outperform” rating and set a $11.00 price target (down previously from $20.00) on shares of Perspective Therapeutics in a report on Thursday, November 21st. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Perspective Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $15.14.

Perspective Therapeutics Stock Up 18.4 %

Shares of NYSE:CATX opened at $4.37 on Monday. The stock has a 50 day moving average of $11.15. Perspective Therapeutics has a twelve month low of $2.28 and a twelve month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last released its earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, hitting analysts’ consensus estimates of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The business had revenue of $0.37 million for the quarter. Equities analysts forecast that Perspective Therapeutics will post -0.86 earnings per share for the current year.

Insider Buying and Selling at Perspective Therapeutics

In related news, CEO Johan M. Spoor acquired 14,500 shares of the company’s stock in a transaction on Monday, November 25th. The shares were purchased at an average price of $3.78 per share, for a total transaction of $54,810.00. Following the purchase, the chief executive officer now owns 152,072 shares in the company, valued at $574,832.16. This represents a 10.54 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 3.52% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in CATX. nVerses Capital LLC bought a new stake in Perspective Therapeutics in the third quarter worth approximately $57,000. US Bancorp DE grew its position in Perspective Therapeutics by 142.7% in the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after acquiring an additional 3,866 shares in the last quarter. Intech Investment Management LLC bought a new stake in Perspective Therapeutics in the third quarter worth approximately $137,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Perspective Therapeutics in the third quarter worth approximately $152,000. Finally, Los Angeles Capital Management LLC bought a new stake in Perspective Therapeutics in the third quarter worth approximately $153,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.